Article Text

Download PDFPDF
Molecular similarities between primary peritoneal and primary ovarian carcinomas
  1. L.-M. Chen*,
  2. S. D. Yamada,
  3. Y.-S. Fu,
  4. R. L. Baldwin§ and
  5. B. Y. Karlan§
  1. * Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California, San Francisco, San Francisco, California
  2. Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Chicago Hospitals, Chicago, Ilinois
  3. Department of Pathology, Providence St. Joseph Medical Center, Burbank, CA
  4. § Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Cedars-Sinai Medical Center and Geffen School of Medicine at UCLA, Los Angeles, California
  1. Address correspondence and reprint requests to: Beth Y. Karlan, MD, Division of Gynecologic Oncology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, #160 W, Los Angeles, CA 90048.
  1. Presented at the American Association of Cancer Research, 1997, San Diego, CA, the Western Association of Gynecologic Oncologists, 1997, Alberta, Canada, and at the Society of Gynecologic Oncologists, 1998, Orlando, FL.


The objective of this paper was to characterize expression patterns of biologic markers to distinguish papillary serous peritoneal carcinoma (PPC) from papillary serous ovarian carcinoma (POC). Immunohistochemical analysis of HER-2/neu, p53, bcl-2, and nm23-H1 expression was performed on archival paraffin-embedded tissues. Antigen expression was compared at ovarian and extra-ovarian sites. Thirty-two PPC cases were compared to 18 POC cases. Mean age, stage, grade, and survival outcome were comparable between the two groups. Antigen expression patterns were not significantly different between PPC and POC for the four markers studied. In all cases, nm23-H1 was expressed. Conversely, bcl-2 was expressed at only a single tissue site in three of 32 (9.4%) PPC cases and in one of 18 (5.6%) POC cases. Eleven of 32 (34.4%) PPC cases overexpressed HER-2/neu, vs. four of 18 (22.2%) POC cases. P53 staining results were positive in 23 of 32 (71.9%) PPC and 13 of 18 (72.2%) POC cases. Intrapatient antigen expression was identical at primary and metastatic tumor sites in 50% of the POC and 48.4% of the PPC cases. We conclude that PPC and POC have a comparable immunohistochemical phenotype for these four molecular markers, which is reflected by their similar clinical courses.

  • HER-2
  • neu
  • ovarian carcinoma
  • peritoneal carcinoma
  • p53

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.